In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
News|Videos|December 9, 2015
How Patient Empowerment Is Affecting Pharmacy Practice
James Hoffman, PharmD, MS, FASHP of St. Jude Children's Research Hospital, describes how the growing trend of patient empowerment will affect the practice of pharmacy going forward.
Advertisement
James Hoffman, PharmD, MS, FASHP of St. Jude Children's Research Hospital, describes how the growing trend of patient empowerment will affect the practice of pharmacy going forward.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.
Advertisement
Related to this article
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5